Initial results from two studies of Stirling Products’ ImmunoXel have shown the drug has immunomodulatory actions with clear effects on cytokine levels and lymphocyte profiles in HIV infections.

The studies were conducted to clarify the efficacy of ImmunoXel in treating and preventing bacterial and viral infections, and to confirm validation of the ImmunoXel mechanism in treating tuberculosis and HIV.

They indicate that ImmunoXel restores the ability of T-cells to proliferate and amplifies antigen-specific immune response in a HIV vaccine model in monkeys.

The final results are expected to point towards positive determination of certain mechanisms of action of ImmunoXel in treating HIV.